FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D C	20540
wasiiiigton,	D.C.	20040

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-02									
	Estimated average burden									
- 1	hours per response.	0.5								

Filed pursuant to	Section 16	3(a) of the	Securities E	xchange	Act of 1	93
or Section	30(h) of th	nè Ínvestm	ent Compai	ny Act of	1940	

1. Name and Address of Reporting Person* <u>Atkins Michael B.</u>				2. Issuer Name and Ticker or Trading Symbol Werewolf Therapeutics, Inc. [HOWL]						(Che	elationship of eck all applice \text{\text{V}}	able)	Person(s) to Iss			
(Last)	`	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/04/2024							Officer below)	(give title	Other (s below)	specify
C/O WEREWOLF THERAPEUTICS, INC. 200 TALCOTT AVENUE, 2ND FLOOR				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) WATER	ГОWN M	Ā	02472		L			4 ()					Form fi Person		han One Repo	rting
(City)	(S	tate)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						d to					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date (Month/D		2A. Deemed Execution Date, if any (Month/Day/Year		Code (Instr. 5)			5. Amour Securitie Beneficia Owned F Reported	s Fally (I ollowing (I	orm: Direct 0) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)						
								Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(11150.4)	
		٦							uired, Dis s, options,				Owned			
Derivative Conversion Date Execut Security or Exercise (Month/Day/Year) if any		3A. Deemed Execution Da if any (Month/Day/\)	ate, Tr	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$5.25	01/04/2024			A		35,000		(1)	01/03/2034	Common Stock	35,000	\$0.00	35,000	D	

Explanation of Responses:

1. The option was granted on January 4, 2024. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter.

> /s/ Jonathan Owen, Attorneyin-fact

** Signature of Reporting Person

01/04/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.